Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Price Target from Brokerages

Shares of Acelyrin, Inc. (NASDAQ:SLRN) have earned an average rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $11.50.

SLRN has been the subject of several recent analyst reports. Morgan Stanley decreased their target price on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, August 19th. Piper Sandler decreased their price objective on Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. HC Wainwright lifted their target price on Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Finally, Wells Fargo & Company increased their price target on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th.

Acelyrin Stock Down 1.9 %

SLRN stock opened at $4.64 on Friday. The stock has a market cap of $465.51 million, a PE ratio of -1.89 and a beta of 1.98. The firm’s 50-day simple moving average is $5.40 and its 200 day simple moving average is $5.03. Acelyrin has a fifty-two week low of $3.36 and a fifty-two week high of $8.89.

Hedge Funds Weigh In On Acelyrin

Several hedge funds have recently made changes to their positions in SLRN. Ameritas Investment Partners Inc. grew its position in Acelyrin by 118.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock worth $49,000 after purchasing an additional 3,921 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Acelyrin during the second quarter valued at $49,000. Virtu Financial LLC purchased a new stake in Acelyrin in the 3rd quarter worth about $50,000. HighTower Advisors LLC acquired a new stake in Acelyrin during the 3rd quarter worth about $50,000. Finally, SG Americas Securities LLC purchased a new position in Acelyrin during the 2nd quarter valued at about $51,000. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.